• Je něco špatně v tomto záznamu ?

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

AJ. Coles, JL. Jones, P. Vermersch, A. Traboulsee, AD. Bass, A. Boster, A. Chan, G. Comi, Ó. Fernández, G. Giovannoni, E. Kubala Havrdova, C. LaGanke, X. Montalban, C. Oreja-Guevara, F. Piehl, H. Wiendl, T. Ziemssen

. 2022 ; 28 (5) : 842-846. [pub] 20211209

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019030

Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35.4%) patients with and 395/1120 (35.3%) without preexisting autoimmunity developed non-MS autoimmunity. Thyroid autoimmunity after alemtuzumab courses 1 or 2 did not increase subsequent non-thyroid autoimmune adverse events. Therefore, autoimmune disease before or after alemtuzumab treatment does not predict autoimmunity after further courses, so should not preclude adequate alemtuzumab dosing to control MS. Finally, post-marketing safety data contribute toward a full record of the alemtuzumab benefit/risk profile for the MS field.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019030
003      
CZ-PrNML
005      
20220804135300.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/13524585211061335 $2 doi
035    __
$a (PubMed)34882037
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Coles, Alasdair J $u Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Cambridge, UK
245    10
$a Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data / $c AJ. Coles, JL. Jones, P. Vermersch, A. Traboulsee, AD. Bass, A. Boster, A. Chan, G. Comi, Ó. Fernández, G. Giovannoni, E. Kubala Havrdova, C. LaGanke, X. Montalban, C. Oreja-Guevara, F. Piehl, H. Wiendl, T. Ziemssen
520    9_
$a Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35.4%) patients with and 395/1120 (35.3%) without preexisting autoimmunity developed non-MS autoimmunity. Thyroid autoimmunity after alemtuzumab courses 1 or 2 did not increase subsequent non-thyroid autoimmune adverse events. Therefore, autoimmune disease before or after alemtuzumab treatment does not predict autoimmunity after further courses, so should not preclude adequate alemtuzumab dosing to control MS. Finally, post-marketing safety data contribute toward a full record of the alemtuzumab benefit/risk profile for the MS field.
650    _2
$a alemtuzumab $x škodlivé účinky $7 D000074323
650    _2
$a autoimunita $7 D015551
650    _2
$a klinické zkoušky, fáze II jako téma $7 D017322
650    _2
$a klinické zkoušky, fáze III jako téma $7 D017326
650    _2
$a lidé $7 D006801
650    _2
$a marketing $7 D040541
650    12
$a roztroušená skleróza $x chemicky indukované $x farmakoterapie $7 D009103
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jones, Joanne L $u Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Cambridge, UK
700    1_
$a Vermersch, Patrick $u Univ. Lille, INSERM UMR-S1172-Lille Neuroscience et Cognition, CHU Lille, FHU Precise, Lille, France
700    1_
$a Traboulsee, Anthony $u The University of British Columbia, Vancouver, BC, Canada
700    1_
$a Bass, Ann D $u Neurology Center of San Antonio, San Antonio, TX, USA
700    1_
$a Boster, Aaron $u Boster MS Center, Columbus, OH, USA $1 https://orcid.org/0000000330569065
700    1_
$a Chan, Andrew $u Bern University Hospital and University of Bern, Bern, Switzerland
700    1_
$a Comi, Giancarlo $u Università Vita Salute San Raffaele, Milan, Italy
700    1_
$a Fernández, Óscar $u Fundacion IMABIS, Hospital Universitario Carlos Haya, Málaga, Spain
700    1_
$a Giovannoni, Gavin $u Barts and The London School of Medicine, Queen Mary University of London, London, UK
700    1_
$a Kubala Havrdova, Eva $u Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic
700    1_
$a LaGanke, Christopher $u North Central Neurology Associates, Cullman, AL, USA
700    1_
$a Montalban, Xavier $u Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain
700    1_
$a Oreja-Guevara, Celia $u Department of Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain/Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain $1 https://orcid.org/0000000292215716
700    1_
$a Piehl, Fredrik $u Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Wiendl, Heinz $u University of Münster, Münster, Germany
700    1_
$a Ziemssen, Tjalf $u Center of Clinical Neuroscience, Department of Neurology Carl Gustav Carus University Hospital, Dresden University of Technology, Dresden, Germany $1 https://orcid.org/0000000343103432
773    0_
$w MED00006389 $t Multiple sclerosis (Houndmills, Basingstoke, England) $x 1477-0970 $g Roč. 28, č. 5 (2022), s. 842-846
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34882037 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135254 $b ABA008
999    __
$a ok $b bmc $g 1822578 $s 1170273
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 28 $c 5 $d 842-846 $e 20211209 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace